Subcutaneous, intramuscular, and even oral routes all show effect, though injectable routes generally show better uptake and more predictable results
The study discussed here was relatively small, involving only 17 patients, and more extensive clinical trials are needed to fully understand: Long-term safety profile Optimal dosing protocols Patient selection criteria Potential side effects Interactions with other treatments Additionally, patients should be aware that BPC-157 is not yet FDA-approved for human use, and treatment is typically offered on a research or compassionate use basis by qualified practitioners
The peptide repairs intestinal mucosal damage, restores tight junction integrity reducing intestinal permeability often called leaky gut, normalizes gastric emptying and intestinal motility, protects against NSAID-induced ulcers, and promotes healing of inflammatory bowel disease lesions
The purchaser and handling laboratory assume full responsibility for proper handling, storage, use, and regulatory compliance in accordance with all applicable local, state, and federal regulations
Has there been research into this treatment